Soumit Roy
Stock Analyst at Edward Jones
(3.45)
# 959
Out of 5,090 analysts
44
Total ratings
30.3%
Success rate
13.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Soumit Roy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVAX Evaxion | Initiates: Buy | $10 | $5.35 | +86.92% | 1 | Oct 30, 2025 | |
| AVXL Anavex Life Sciences | Downgrades: Hold | n/a | $4.42 | - | 1 | Oct 24, 2025 | |
| CGON CG Oncology | Initiates: Buy | $50 | $44.95 | +11.23% | 1 | Sep 8, 2025 | |
| TARA Protara Therapeutics | Initiates: Buy | $21 | $6.85 | +206.57% | 1 | May 22, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $40 | $24.21 | +65.22% | 1 | May 20, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Buy | $36 → $27 | $21.55 | +25.32% | 2 | May 16, 2025 | |
| ACRV Acrivon Therapeutics | Downgrades: Hold | n/a | $2.44 | - | 2 | May 16, 2025 | |
| ONCY Oncolytics Biotech | Downgrades: Hold | n/a | $0.98 | - | 2 | May 16, 2025 | |
| MURA Mural Oncology | Downgrades: Hold | n/a | $2.03 | - | 2 | Mar 25, 2025 | |
| CRVO CervoMed | Upgrades: Buy | $15 | $9.00 | +66.67% | 3 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $8.31 | +20.34% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $34 | $29.01 | +17.20% | 2 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $1.84 | +1,856.52% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $2.64 | +1,112.12% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $8.34 | +7.98% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $11.41 | +48.99% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $2.44 | +432.79% | 1 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $4 | $0.56 | +608.34% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $3.32 | - | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $5.15 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $26 | $10.59 | +145.51% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $16.38 | +327.35% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $79.63 | -87.44% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $5.74 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $80 | $16.55 | +383.38% | 1 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.52 | - | 2 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $2.03 | +15,663.55% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $810 | $5.04 | +15,987.39% | 1 | Feb 24, 2021 |
Evaxion
Oct 30, 2025
Initiates: Buy
Price Target: $10
Current: $5.35
Upside: +86.92%
Anavex Life Sciences
Oct 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $4.42
Upside: -
CG Oncology
Sep 8, 2025
Initiates: Buy
Price Target: $50
Current: $44.95
Upside: +11.23%
Protara Therapeutics
May 22, 2025
Initiates: Buy
Price Target: $21
Current: $6.85
Upside: +206.57%
ArriVent BioPharma
May 20, 2025
Initiates: Buy
Price Target: $40
Current: $24.21
Upside: +65.22%
Enliven Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $36 → $27
Current: $21.55
Upside: +25.32%
Acrivon Therapeutics
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.44
Upside: -
Oncolytics Biotech
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.98
Upside: -
Mural Oncology
Mar 25, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.03
Upside: -
CervoMed
Mar 13, 2025
Upgrades: Buy
Price Target: $15
Current: $9.00
Upside: +66.67%
Mar 12, 2025
Initiates: Buy
Price Target: $10
Current: $8.31
Upside: +20.34%
Mar 10, 2025
Upgrades: Buy
Price Target: $34
Current: $29.01
Upside: +17.20%
Feb 11, 2025
Upgrades: Buy
Price Target: $36
Current: $1.84
Upside: +1,856.52%
Jan 28, 2025
Initiates: Buy
Price Target: $32
Current: $2.64
Upside: +1,112.12%
Oct 31, 2024
Initiates: Buy
Price Target: $9
Current: $8.34
Upside: +7.98%
Oct 31, 2024
Initiates: Buy
Price Target: $17
Current: $11.41
Upside: +48.99%
Sep 17, 2024
Initiates: Buy
Price Target: $13
Current: $2.44
Upside: +432.79%
Sep 11, 2024
Maintains: Buy
Price Target: $6 → $4
Current: $0.56
Upside: +608.34%
Jul 1, 2024
Downgrades: Hold
Price Target: n/a
Current: $3.32
Upside: -
May 15, 2024
Downgrades: Hold
Price Target: n/a
Current: $5.15
Upside: -
Apr 17, 2024
Maintains: Buy
Price Target: $22 → $26
Current: $10.59
Upside: +145.51%
Apr 16, 2024
Initiates: Buy
Price Target: $70
Current: $16.38
Upside: +327.35%
Apr 11, 2024
Upgrades: Buy
Price Target: $10
Current: $79.63
Upside: -87.44%
May 23, 2023
Downgrades: Hold
Price Target: n/a
Current: $5.74
Upside: -
Apr 19, 2023
Initiates: Buy
Price Target: $80
Current: $16.55
Upside: +383.38%
Nov 16, 2022
Downgrades: Hold
Price Target: n/a
Current: $1.52
Upside: -
Nov 8, 2022
Initiates: Buy
Price Target: $320
Current: $2.03
Upside: +15,663.55%
Feb 24, 2021
Initiates: Buy
Price Target: $810
Current: $5.04
Upside: +15,987.39%